Menu
Forums
New posts
Search forums
What's new
New posts
New profile posts
Latest activity
Vault
Time Travel Schematics
T.E.C. Time Archive
The Why Files
Have You Seen...?
Chronovisor
TimeTravelForum.tk
TimeTravelForum.net
ParanormalNetwork.net
Paranormalis.com
ConspiracyCafe.net
Streams
Live streams
Featured streams
Multi-Viewer
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Paranormal Forum
Health, Well-Being & Alternative Medicine
Need health? Go take a PEA
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="OakFieldAlienz444" data-source="post: 253199" data-attributes="member: 12609"><p>from Wikipedia:</p><p></p><p><strong>Palmitoylethanolamide</strong> (<strong>PEA</strong>) is an endogenous <a href="https://en.wikipedia.org/wiki/Fatty_acid_amide" target="_blank">fatty acid amide</a>, and lipid modulator <a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-pmid:_27539936-2" target="_blank">[2]</a> PEA has been studied in <em>in vitro</em> and <em>in vivo</em> systems using exogenously added or dosed compound; there is evidence that it binds to a nuclear receptor,<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-O%27Sullivan-3" target="_blank">[3]</a> through which it exerts a variety of biological effects, some related to chronic inflammation and pain.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-pmid:_27539936-2" target="_blank">[2]</a></p><p></p><p>A main target of PEA is proposed to be the <a href="https://en.wikipedia.org/wiki/Peroxisome_proliferator-activated_receptor_alpha" target="_blank">peroxisome proliferator-activated receptor alpha</a> (PPAR-α).<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-O%27Sullivan-3" target="_blank">[3]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-LoVerme2005-4" target="_blank">[4]</a> PEA also has affinity to cannabinoid-like G-coupled receptors <a href="https://en.wikipedia.org/wiki/GPR55" target="_blank">GPR55</a> and <a href="https://en.wikipedia.org/wiki/GPR119" target="_blank">GPR119</a>.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Godlewski2009-5" target="_blank">[5]</a> PEA cannot strictly be considered a classic <a href="https://en.wikipedia.org/wiki/Endocannabinoid_system" target="_blank">endocannabinoid</a> because it lacks affinity for the cannabinoid receptors <a href="https://en.wikipedia.org/wiki/CB1_receptor" target="_blank">CB1</a> and <a href="https://en.wikipedia.org/wiki/CB2_receptor" target="_blank">CB2</a>.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-O-6" target="_blank">[6]</a> However, primary research supports the conclusion that the presence of PEA (or other structurally related <a href="https://en.wikipedia.org/wiki/N-acylethanolamine" target="_blank">N-acylethanolamines</a>) enhances <a href="https://en.wikipedia.org/wiki/Anandamide" target="_blank">anandamide</a> activity by an "<a href="https://en.wikipedia.org/wiki/Entourage_effect" target="_blank">entourage effect</a>".<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-7" target="_blank">[7]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-8" target="_blank">[8]</a>[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources" target="_blank">non-primary source needed</a></em>]</p><p></p><p>Some primary research reports support the conclusion that PEA levels are altered and that the endocannabinoid system (ECS) is "imbalanced" in acute and chronic inflammation.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-9" target="_blank">[9]</a>[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources" target="_blank">non-primary source needed</a></em>] A primary research article, for instance, has reported that the deregulation of cannabinoid receptors and their endogenous <a href="https://en.wikipedia.org/wiki/Ligand_(biochemistry)" target="_blank">ligands</a> accompanies the development and progression of β-amyloid-induced neuroinflammation.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-D%27Agostino_G-10" target="_blank">[10]</a>[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources" target="_blank">non-primary source needed</a></em>]</p><p></p><p>In some primary research studies,[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources" target="_blank">non-primary source needed</a></em>] PEA has been shown to have <a href="https://en.wikipedia.org/wiki/Inflammation" target="_blank">anti-inflammatory</a>,<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-LoVerme2005-4" target="_blank">[4]</a> <a href="https://en.wikipedia.org/wiki/Anti-nociceptive" target="_blank">anti-nociceptive</a>,<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Calignano2001-11" target="_blank">[11]</a> neuroprotective,<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Koch2011-12" target="_blank">[12]</a> and <a href="https://en.wikipedia.org/wiki/Anticonvulsant" target="_blank">anticonvulsant</a> properties.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Lambert2001-13" target="_blank">[13]</a></p><p></p><h2>Early and recent studies[<a href="https://en.wikipedia.org/w/index.php?title=Palmitoylethanolamide&action=edit&section=1" target="_blank">edit</a>]</h2> <table style='width: 100%'><tr><td><a href="https://en.wikipedia.org/wiki/File:Question_book-new.svg" target="_blank"><img src="https://upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png" alt="" class="fr-fic fr-dii fr-draggable " style="" /></a></td><td>This section <strong>needs additional citations for <a href="https://en.wikipedia.org/wiki/Wikipedia:Verifiability" target="_blank">verification</a></strong>. Please help <a href="https://en.wikipedia.org/wiki/Special:EditPage/Palmitoylethanolamide" target="_blank">improve this article</a> by <a href="https://en.wikipedia.org/wiki/Help:Referencing_for_beginners" target="_blank">adding citations to reliable sources</a> in this section. Unsourced material may be challenged and removed. <em>(February 2020) (<a href="https://en.wikipedia.org/wiki/Help:Maintenance_template_removal" target="_blank">Learn how and when to remove this template message</a>)</em></td></tr></table><p>Palmitoylethanolamide was discovered in 1957.[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Citation_needed" target="_blank">citation needed</a></em>] Indications for its use as an anti-inflammatory and analgesic date from before 1980.[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Citation_needed" target="_blank">citation needed</a></em>] In that year, researchers described what they called "N-(2-hydroxyethyl)-palmitamide" as a natural anti-inflammatory agent, stating, "We have succeeded in isolating a crystalline anti-inflammatory factor from soybean lecithin and identifying it as (<em>S</em>)-(2-hydroxyethyl)-palmitamide. The compound also was isolated from a phospholipid fraction of egg yolk and from hexane-extracted peanut meal."[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Inline_citation#When_you_must_use_inline_citations" target="_blank">This quote needs a citation</a></em>]</p><p></p><p>In 1975, Czech physicians described the results of a clinical trial[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Please_clarify" target="_blank">clarification needed</a></em>] looking at joint pain, where the analgesic action of <a href="https://en.wikipedia.org/wiki/Aspirin" target="_blank">aspirin</a> versus PEA were tested; both drugs were reported to enhance joint movements and decrease pain.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Masek1975-14" target="_blank">[14]</a> In 1970 the drug manufacturer <a href="https://en.wikipedia.org/w/index.php?title=Spofa&action=edit&redlink=1" target="_blank">Spofa</a> in Czechoslovakia introduced <a href="https://en.wikipedia.org/w/index.php?title=Impulsin&action=edit&redlink=1" target="_blank">Impulsin</a>, a tablet dose of PEA, for the treatment and prophylaxis of influenza and other respiratory infections.[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Citation_needed" target="_blank">citation needed</a></em>] In Spain, the company <a href="https://en.wikipedia.org/wiki/Almirall" target="_blank">Almirall</a> introduced <a href="https://en.wikipedia.org/wiki/Palmidrol" target="_blank">Palmidrol</a> in tablet and suspension forms in 1976, for the same indications.[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Citation_needed" target="_blank">citation needed</a></em>]</p><p></p><p>In the mid-1990s, the relationship between <a href="https://en.wikipedia.org/wiki/Anandamide" target="_blank">anandamide</a> and PEA was described;<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Facci1995-15" target="_blank">[15]</a>[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources" target="_blank">non-primary source needed</a></em>] the expression of <a href="https://en.wikipedia.org/wiki/Mast_cell" target="_blank">mast cell</a> receptors sensitive to the two molecules was demonstrated by <a href="https://en.wikipedia.org/wiki/Rita_Levi-Montalcini" target="_blank">Levi-Montalcini</a> and coworkers.[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Manual_of_Style/Words_to_watch#Unsupported_attributions" target="_blank">according to whom?</a></em>][<em><a href="https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources" target="_blank">non-primary source needed</a></em>] During this period, more insight into the functions of endogenous fatty acid derivatives emerged, and compounds such as <a href="https://en.wikipedia.org/wiki/Oleamide" target="_blank">oleamide</a>, palmitoylethanolamide, <a href="https://en.wikipedia.org/w/index.php?title=2-lineoylglycerol&action=edit&redlink=1" target="_blank">2-lineoylglycerol</a> and <a href="https://en.wikipedia.org/w/index.php?title=2-palmitoylglycerol&action=edit&redlink=1" target="_blank">2-palmitoylglycerol</a> were explored for their capacity to modulate pain sensitivity and inflammation via what at that time was thought to be the endocannabinoid signalling pathway.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Walker2002-16" target="_blank">[16]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Lambert2002-17" target="_blank">[17]</a></p><p></p><p>Primary reports also have provided evidence that PEA downregulates hyperactive mast cells in a dose-dependent manner,<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Mazzari1996-18" target="_blank">[18]</a> and that it alleviates pain elicited in mouse models.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Calignano2001-11" target="_blank">[11]</a>[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Verifiability" target="_blank">verification needed</a></em>] PEA and related compounds such as anandamide also seem to have synergistic effects in models of pain and analgesia.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Calignano1998-19" target="_blank">[19]</a></p><p></p><h2>Animal models[<a href="https://en.wikipedia.org/w/index.php?title=Palmitoylethanolamide&action=edit&section=2" target="_blank">edit</a>]</h2><p>In a variety of animal models, PEA seems to have some promise;[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:EDITORIALIZING" target="_blank">editorializing</a></em>][<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Citation_needed" target="_blank">citation needed</a></em>] researchers have been able to demonstrate relevant clinical efficacy in a variety of disorders, from multiple sclerosis to neuropathic pain.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Lor%C3%ADa2008-20" target="_blank">[20]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Costa2008-21" target="_blank">[21]</a></p><p></p><p>In the mouse <a href="https://en.wikipedia.org/wiki/Behavioural_despair_test" target="_blank">forced swimming test</a>, palmitoylethanolamide was comparable to <a href="https://en.wikipedia.org/wiki/Fluoxetine" target="_blank">fluoxetine</a> for <a href="https://en.wikipedia.org/wiki/Depression_(mood)" target="_blank">depression</a>.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Yu2011-22" target="_blank">[22]</a> An Italian study published in 2011 found that PEA reduced the raised <a href="https://en.wikipedia.org/wiki/Intraocular_pressure" target="_blank">intraocular pressure</a> of <a href="https://en.wikipedia.org/wiki/Glaucoma" target="_blank">glaucoma</a>.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Gagliano2011-23" target="_blank">[23]</a> In a spinal trauma model, PEA reduced the resulting neurological deficit via the reduction of mast cell infiltration and activation. PEA in this model also reduced the activation of <a href="https://en.wikipedia.org/wiki/Microglia" target="_blank">microglia</a> and <a href="https://en.wikipedia.org/wiki/Astrocytes" target="_blank">astrocytes</a>.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Esposito2011-24" target="_blank">[24]</a> Its activity as an inhibitor of inflammation counteracts reactive <a href="https://en.wikipedia.org/wiki/Astrogliosis" target="_blank">astrogliosis</a> induced by <a href="https://en.wikipedia.org/wiki/Beta-amyloid" target="_blank">beta-amyloid</a> peptide, in a model relevant for neurodegeneration, probably via the <a href="https://en.wikipedia.org/wiki/Peroxisome_proliferator-activated_receptor_alpha" target="_blank">PPAR-α</a> mechanism of action.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Scuderi2011-25" target="_blank">[25]</a>[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Verifiability" target="_blank">verification needed</a></em>] In models of stroke and other <a href="https://en.wikipedia.org/wiki/Central_nervous_system" target="_blank">CNS</a> trauma, PEA exerted neuroprotective properties.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Koch2011-12" target="_blank">[12]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Hansen2010-26" target="_blank">[26]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Garcia-Ovejero2011-27" target="_blank">[27]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Schomacher2008-28" target="_blank">[28]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Skaper1996-29" target="_blank">[29]</a></p><p></p><h2>Animal models of chronic pain and inflammation[<a href="https://en.wikipedia.org/w/index.php?title=Palmitoylethanolamide&action=edit&section=3" target="_blank">edit</a>]</h2><p>Chronic pain and neuropathic pain are indications for which there is high unmet need in the clinic. PEA has been tested in a variety of animal models for chronic and neuropathic pain, because cannabinoids, such as <a href="https://en.wikipedia.org/wiki/THC" target="_blank">THC</a>, have been proven to be effective in neuropathic pain states.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Ware2010-30" target="_blank">[30]</a> The analgesic and antihyperalgesic effects of PEA in two models of acute and persistent pain seemed to be explained at least partly via the <em>de novo</em> neurosteroid synthesis.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Sasso2011-31" target="_blank">[31]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Raso2011-32" target="_blank">[32]</a> In chronic <a href="https://en.wikipedia.org/wiki/Granulomatous" target="_blank">granulomatous</a> pain and inflammation model, PEA could prevent nerve formation and sprouting, mechanical allodynia, and PEA inhibited <a href="https://en.wikipedia.org/wiki/Dorsal_root_ganglia" target="_blank">dorsal root ganglia</a> activation, which is a hallmark for winding up in neuropathic pain.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-DeFilippis2011-33" target="_blank">[33]</a> The mechanism of action of PEA as an analgesic and anti-inflammatory molecule is probably based on different aspects.[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:EDITORIALIZING" target="_blank">editorializing</a></em>][<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Citation_needed" target="_blank">citation needed</a></em>] PEA inhibits the release of both preformed and newly synthesised mast cell mediators, such as <a href="https://en.wikipedia.org/wiki/Histamine" target="_blank">histamine</a> and <a href="https://en.wikipedia.org/wiki/TNF-alpha" target="_blank">TNF-alpha</a>.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Cerrato2010-34" target="_blank">[34]</a> PEA, as well as its analogue adelmidrol (di-amide derivative of azelaic acid), can both down-regulate mast cells.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-DeFilippis2009-35" target="_blank">[35]</a> PEA reduces the expression of <a href="https://en.wikipedia.org/wiki/Cyclooxygenase-2" target="_blank">cyclooxygenase-2</a> (COX-2) and <a href="https://en.wikipedia.org/wiki/Inducible_nitric_oxide_synthase" target="_blank">inducible nitric oxide synthase</a> (iNOS) and prevents IkB-alpha degradation and p65 <a href="https://en.wikipedia.org/wiki/NF-kappaB" target="_blank">NF-kappaB</a> nuclear translocation, the latter related to PEA as an endogenous PPAR-alpha agonist. In 2012 it became clear that PEA can also reduce reperfusion injury and the negative impact of shock on various outcome parameters, such as renal dysfunction, ischemic injury and inflammation, most probably via the PPAR-alpha pathway.[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:EDITORIALIZING" target="_blank">editorializing</a></em>][<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Citation_needed" target="_blank">citation needed</a></em>] Studies have shown that PEA activates activates PPAR-alpha and TRPV1 receptors that control inflammation and the sensation of pain.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-36" target="_blank">[36]</a> Among the reperfusion and inflammation markers measured PEA could reduce the increase in creatinine, γGT, AST, nuclear translocation of NF-κBp65; kidney MPO activity and MDA levels, nitrotyrosine, PAR and adhesion molecules expression, the infiltration and activation of mast cells and apoptosis.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-DiPaola-37" target="_blank">[37]</a></p><p></p><p>The biological responses to PEA dosing in animal models and in humans are being investigated vis-à-vis its involvement in a repair mechanism relevant to patient conditions of chronic inflammation and chronic pain.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Darmani2005-38" target="_blank">[38]</a>[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Verifiability" target="_blank">verification needed</a></em>] In a model of visceral pain (inflammation of the <a href="https://en.wikipedia.org/wiki/Urinary_bladder" target="_blank">urinary bladder</a>) PEA was able to attenuate the viscero-visceral hyper-reflexia induced by inflammation of the urinary bladder, one of the reasons why PEA is currently explored in the painful bladder syndrome.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Jaggar1998-39" target="_blank">[39]</a> In a different model for bladder pain, the turpentine-induced urinary bladder inflammation in the rat, PEA also attenuated a referred hyperalgesia in a dose-dependent way.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Farquhar-Smith2001-40" target="_blank">[40]</a> Chronic pelvic pain in patients seem to respond favourably to a treatment with PEA.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Calabr%C3%B2i2010-41" target="_blank">[41]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Indraccoloi2010-42" target="_blank">[42]</a></p><p></p><h2>Activity in non-neuronal cells[<a href="https://en.wikipedia.org/w/index.php?title=Palmitoylethanolamide&action=edit&section=4" target="_blank">edit</a>]</h2> <table style='width: 100%'><tr><td><a href="https://en.wikipedia.org/wiki/File:Question_book-new.svg" target="_blank"><img src="https://upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png" alt="" class="fr-fic fr-dii fr-draggable " style="" /></a></td><td>This section <strong>needs additional citations for <a href="https://en.wikipedia.org/wiki/Wikipedia:Verifiability" target="_blank">verification</a></strong>. Please help <a href="https://en.wikipedia.org/wiki/Special:EditPage/Palmitoylethanolamide" target="_blank">improve this article</a> by <a href="https://en.wikipedia.org/wiki/Help:Referencing_for_beginners" target="_blank">adding citations to reliable sources</a> in this section. Unsourced material may be challenged and removed. <em>(February 2020) (<a href="https://en.wikipedia.org/wiki/Help:Maintenance_template_removal" target="_blank">Learn how and when to remove this template message</a>)</em></td></tr></table><p>PEA, as an <a href="https://en.wikipedia.org/wiki/N-acylethanolamine" target="_blank"><em>N</em>-acylethanolamine</a>, has physico-chemical properties comparable to <a href="https://en.wikipedia.org/wiki/Anandamide" target="_blank">anandamide</a>,[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Please_clarify" target="_blank">clarification needed</a></em>] and, while it is not strictly an endocannabinoid, it is often studied in conjunction with anandamide because of their overlapping synthetic and metabolic pathways.[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources" target="_blank">non-primary source needed</a></em>] <em>N</em>-acylethanolamines such as PEA often act as signaling molecules, activating receptors and regulating a variety of physiological functions.[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources" target="_blank">non-primary source needed</a></em>] PEA is known to activate intracellular, nuclear and membrane-associated receptors,[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources" target="_blank">non-primary source needed</a></em>] and to regulate many physiological functions related to the inflammatory cascade and chronic pain states.[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources" target="_blank">non-primary source needed</a></em>] Endocannabinoid lipids like PEA are widely distributed in nature, in a variety of plant, invertebrate, and mammalian tissues.[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources" target="_blank">non-primary source needed</a></em>]</p><p></p><p>PEA's mechanism of action sometimes is described as <a href="https://en.wikipedia.org/wiki/Autacoid" target="_blank">Autacoid</a> Local Injury Antagonism (acronym ALIA),<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Facci1995-15" target="_blank">[15]</a> and PEA under this nomenclature is an <a href="https://en.wikipedia.org/w/index.php?title=ALIAmide&action=edit&redlink=1" target="_blank">ALIAmide</a>. <a href="https://en.wikipedia.org/wiki/Rita_Levi-Montalcini" target="_blank">Levi-Montalcini</a> and coworkers presented evidence in 1993 that lipid amides of the N-acylethanolamine type, such as PEA, are potential prototypes of naturally occurring molecules capable of modulating mast cell activation, and her group used the acronym ALIA in that report.[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources" target="_blank">non-primary source needed</a></em>]<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Aloe1993-43" target="_blank">[43]</a> An <a href="https://en.wikipedia.org/wiki/Autocoid" target="_blank">autocoid</a> is a regulating molecule, locally produced. An ALIAmide is an autocoid synthesized on-demand in response to injury, and acts locally to counteract such pathology. Soon after the breakthrough paper of Levi-Montalcini, the mast cell appeared to be an important target for the anti-inflammatory activity of PEA. Since 1993, at least 25 papers have been published on the various effects of PEA on mast cells. These cells are often found in proximity to sensory nerve endings, and their degranulation can enhance the nociceptive signal, the reason why peripheral mast cells are considered to be pro-inflammatory and pro-nociceptive.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Xanthos2011-44" target="_blank">[44]</a> PEA's activity is currently seen as a new inroad in the treatment of neuropathic pain and related disorders based on overactivation of glia and glia-related cells, such as in diabetes and glaucoma.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Donvito2015-45" target="_blank">[45]</a> Microglia plays a key role in the <a href="https://en.wikipedia.org/wiki/Pain_wind-up" target="_blank">winding up phenomenon</a> and central sensitization.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Nakagawa2010-46" target="_blank">[46]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Guasti2009-47" target="_blank">[47]</a></p><p></p><h2>Clinical relevance[<a href="https://en.wikipedia.org/w/index.php?title=Palmitoylethanolamide&action=edit&section=5" target="_blank">edit</a>]</h2><p>Effects of oral dosing of PEA has been explored in humans, and include clinical trials for a variety of pain states, for inflammatory and pain syndromes.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Indraccoloi2010-42" target="_blank">[42]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-O%27Sullivan2010-48" target="_blank">[48]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Conigliaro2011-49" target="_blank">[49]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Phan2010-50" target="_blank">[50]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Cerrato2011-51" target="_blank">[51]</a> Daily doses range from 300 to 1200 mg per day.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-52" target="_blank">[52]</a> In a 2017 systematic meta-analysis involving 10 studies including data from 786 patients receiving PEA for pain-related indications and 512 controls, PEA was found to be associated with pain reduction significantly greater than observed in controls (<em>P</em> < 0.001).<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-53" target="_blank">[53]</a> Positive influences have also been observed in dermal applications, specifically atopic eczema, which may be linked to PPAR alpha activation.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-O%27Sullivan2010-48" target="_blank">[48]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Hatano2010-54" target="_blank">[54]</a>[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Verifiability" target="_blank">verification needed</a></em>]</p><p></p><p>In a 2015 analysis of a double blind placebo controlled study of PEA in sciatic pain, the Numbers Needed to Treat was 1.5. Its positive influence in chronic pain, and inflammatory states such as atopic eczema, seems[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:EDITORIALIZING" target="_blank">editorializing</a></em>] to originate mainly from PPAR alpha activation.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-O%27Sullivan2010-48" target="_blank">[48]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Hatano2010-54" target="_blank">[54]</a>[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Verifiability" target="_blank">verification needed</a></em>] Since 2012 a number of new trials have been published, among which studies in glaucoma.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Costagliola2014-55" target="_blank">[55]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Pescosolido2014-56" target="_blank">[56]</a> PEA also seems[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:EDITORIALIZING" target="_blank">editorializing</a></em>] to be one of the factors responsible for the decrease in pain sensitivity during and after sport, comparable to the endogenous opiates (endorphines).<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Koltyn2014-57" target="_blank">[57]</a>[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Verifiability" target="_blank">verification needed</a></em>]</p><p></p><p>From a clinical perspective the most important and promising indications for PEA are linked to neuropathic and chronic pain states, such as diabetic neuropathic pain, sciatic pain, CRPS, pelvic pain and entrapment neuropathic pain states.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Darmani2005-38" target="_blank">[38]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Indraccoloi2010-42" target="_blank">[42]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Conigliaro2011-49" target="_blank">[49]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Phan2010-50" target="_blank">[50]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Petrosino2010-58" target="_blank">[58]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-pmid23658493-59" target="_blank">[59]</a> In a blind trial reported in a conference proceeding, patients affected by pain from <a href="https://en.wikipedia.org/wiki/Synovitis" target="_blank">synovitis</a> or <a href="https://en.wikipedia.org/wiki/Temporomandibular_joint" target="_blank">TMJ</a> osteoarthritis (N=25, in total[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Please_clarify" target="_blank">clarification needed</a></em>]) were randomly assigned to PEA or ibuprofen groups for two weeks; the decrease in pain reported after two weeks was significantly higher for the PEA-treated group, likewise for improved masticatory function.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-60" target="_blank">[60]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-61" target="_blank">[61]</a>[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:NOTRS" target="_blank">better source needed</a></em>] In 2012, 20 patients with thalidomide and bortezomib induced neuropathy were reported to have improved nerve functions and less pain after a two-month treatment with PEA.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Truini2012-62" target="_blank">[62]</a> The authors pointed out that although a placebo effect might play a role in the reported pain relief, the changes in neurophysiological measures clearly indicated that PEA exerted a positive action on the myelinated fibre groups. Sixteen men and fourteen women with two major types of neuropathic pain refractory to analgesic treatment—peripheral diabetic neuropathy (4 men, 7 women) or post-herpetic neuralgia (12 men, 7 women)<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-63" target="_blank">[63]</a>—whose symptoms spanned eight pain categories ("burning", "osteoarticular", "piercing", etc.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-64" target="_blank">[64]</a>) who were under prior treatment with pregabalin were transferred to PEA, after which pregabalin treatment was gradually reintroduced; all were responding well after 45 days, and presented significant decreases in pain scores (without drug-drug interactions).[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Verifiability" target="_blank">verification needed</a></em>]<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-65" target="_blank">[65]</a></p><p></p><p>In 2013, a metareview was published on the clinical efficacy and safety of PEA in the treatment of the <a href="https://en.wikipedia.org/wiki/Common_cold" target="_blank">common cold</a> and <a href="https://en.wikipedia.org/wiki/Influenza" target="_blank">influenza</a>, based on reports from six double-blind, placebo, <a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial" target="_blank">randomized controlled trials</a>,[<em><a href="https://en.wikipedia.org/wiki/Wikipedia:Verifiability" target="_blank">verification needed</a></em>] addressing PEA's proposed anti-inflammatory and retinoprotectant effects.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-pmid24066256-66" target="_blank">[66]</a></p><p></p><p>In 2019, significant increases in <a href="https://en.wikipedia.org/wiki/Fatty_acid_amides" target="_blank">fatty acid amides</a> including PEA, <a href="https://en.wikipedia.org/wiki/Arachidonoylethanolamide" target="_blank">arachidonoylethanolamide</a>, and <a href="https://en.wikipedia.org/wiki/Oleoylethanolamide" target="_blank">oleoylethanolamide</a> were noted in a Scottish woman with a previously undocumented variant of <a href="https://en.wikipedia.org/wiki/Congenital_insensitivity_to_pain" target="_blank">congenital insensitivity to pain</a>. This was found to be a result of a combination of a hypomorphic <a href="https://en.wikipedia.org/wiki/Single_nucleotide_polymorphism" target="_blank">single nucleotide polymorphism</a> of <a href="https://en.wikipedia.org/wiki/Fatty_acid_amide_hydrolase" target="_blank">fatty acid amide hydrolase</a> (FAAH), alongside a mutation of the <a href="https://en.wikipedia.org/wiki/Pseudogene" target="_blank">pseudogene</a>, <a href="https://en.wikipedia.org/wiki/FAAH-OUT" target="_blank">FAAH-OUT</a>. The pseudogene was previously considered to be <a href="https://en.wikipedia.org/wiki/Non-coding_DNA" target="_blank">non-coding DNA</a>, FAAH-OUT was found to be capable of modulating the expression of FAAH, making it a possible future target for novel analgesia/anxiolytic drug development.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-67" target="_blank">[67]</a><a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-68" target="_blank">[68]</a></p><p></p><p>In 2020, PEA has been suggested as a drug that may prove beneficial for the treatment of lung inflammation caused by SARS-CoV-2 infection.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-69" target="_blank">[69]</a> A pharmaceutical company called FSD Pharma have entered PEA into a Phase 1 clinical trial under the name FSD-201, and has approval from the FDA for progressing to Phase 2a for this indication.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-70" target="_blank">[70]</a></p><p></p><h2>Metabolism[<a href="https://en.wikipedia.org/w/index.php?title=Palmitoylethanolamide&action=edit&section=6" target="_blank">edit</a>]</h2><p>PEA is metabolized by the cellular enzymes <a href="https://en.wikipedia.org/wiki/Fatty_acid_amide_hydrolase" target="_blank">fatty acid amide hydrolase</a> (FAAH) and <a href="https://en.wikipedia.org/wiki/N-acylethanolamine_acid_amide_hydrolase" target="_blank">N-acylethanolamine acid amide hydrolase</a> (NAAA), the latter of which has more specificity toward PEA over other fatty acid amides.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Tsuboi2007-71" target="_blank">[71]</a></p><p></p><h2>Safety[<a href="https://en.wikipedia.org/w/index.php?title=Palmitoylethanolamide&action=edit&section=7" target="_blank">edit</a>]</h2><p>PEA is generally considered safe, and without adverse drug reactions (ADRs) or drug interactions. A 2016 study assessing safety claims in sixteen clinical trials, six case reports/pilot studies and a meta‐analysis of PEA as an analgesic, concluded that for treatment periods up to 49 days, clinical data argued against serious ADRs at an incidence of 1/200 or greater.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-72" target="_blank">[72]</a> A 2016 pooled meta-analysis involving twelve studies found that no serious ADRs were registered and/or reported.<a href="https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-73" target="_blank">[73]</a> No data on interactions with PEA have been reported. Based on its mechanism, PEA may be considered likely to interact with other PPAR-α agonists used to treat high triglycerides; this remains unconfirmed.</p></blockquote><p></p>
[QUOTE="OakFieldAlienz444, post: 253199, member: 12609"] from Wikipedia: [B]Palmitoylethanolamide[/B] ([B]PEA[/B]) is an endogenous [URL='https://en.wikipedia.org/wiki/Fatty_acid_amide']fatty acid amide[/URL], and lipid modulator [URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-pmid:_27539936-2'][2][/URL] PEA has been studied in [I]in vitro[/I] and [I]in vivo[/I] systems using exogenously added or dosed compound; there is evidence that it binds to a nuclear receptor,[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-O%27Sullivan-3'][3][/URL] through which it exerts a variety of biological effects, some related to chronic inflammation and pain.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-pmid:_27539936-2'][2][/URL] A main target of PEA is proposed to be the [URL='https://en.wikipedia.org/wiki/Peroxisome_proliferator-activated_receptor_alpha']peroxisome proliferator-activated receptor alpha[/URL] (PPAR-α).[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-O%27Sullivan-3'][3][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-LoVerme2005-4'][4][/URL] PEA also has affinity to cannabinoid-like G-coupled receptors [URL='https://en.wikipedia.org/wiki/GPR55']GPR55[/URL] and [URL='https://en.wikipedia.org/wiki/GPR119']GPR119[/URL].[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Godlewski2009-5'][5][/URL] PEA cannot strictly be considered a classic [URL='https://en.wikipedia.org/wiki/Endocannabinoid_system']endocannabinoid[/URL] because it lacks affinity for the cannabinoid receptors [URL='https://en.wikipedia.org/wiki/CB1_receptor']CB1[/URL] and [URL='https://en.wikipedia.org/wiki/CB2_receptor']CB2[/URL].[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-O-6'][6][/URL] However, primary research supports the conclusion that the presence of PEA (or other structurally related [URL='https://en.wikipedia.org/wiki/N-acylethanolamine']N-acylethanolamines[/URL]) enhances [URL='https://en.wikipedia.org/wiki/Anandamide']anandamide[/URL] activity by an "[URL='https://en.wikipedia.org/wiki/Entourage_effect']entourage effect[/URL]".[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-7'][7][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-8'][8][/URL][[I][URL='https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources']non-primary source needed[/URL][/I]] Some primary research reports support the conclusion that PEA levels are altered and that the endocannabinoid system (ECS) is "imbalanced" in acute and chronic inflammation.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-9'][9][/URL][[I][URL='https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources']non-primary source needed[/URL][/I]] A primary research article, for instance, has reported that the deregulation of cannabinoid receptors and their endogenous [URL='https://en.wikipedia.org/wiki/Ligand_(biochemistry)']ligands[/URL] accompanies the development and progression of β-amyloid-induced neuroinflammation.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-D%27Agostino_G-10'][10][/URL][[I][URL='https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources']non-primary source needed[/URL][/I]] In some primary research studies,[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources']non-primary source needed[/URL][/I]] PEA has been shown to have [URL='https://en.wikipedia.org/wiki/Inflammation']anti-inflammatory[/URL],[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-LoVerme2005-4'][4][/URL] [URL='https://en.wikipedia.org/wiki/Anti-nociceptive']anti-nociceptive[/URL],[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Calignano2001-11'][11][/URL] neuroprotective,[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Koch2011-12'][12][/URL] and [URL='https://en.wikipedia.org/wiki/Anticonvulsant']anticonvulsant[/URL] properties.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Lambert2001-13'][13][/URL] [HEADING=1]Early and recent studies[[URL='https://en.wikipedia.org/w/index.php?title=Palmitoylethanolamide&action=edit§ion=1']edit[/URL]][/HEADING] [TABLE] [TR] [TD][URL='https://en.wikipedia.org/wiki/File:Question_book-new.svg'][IMG]https://upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png[/IMG][/URL][/TD] [TD]This section [B]needs additional citations for [URL='https://en.wikipedia.org/wiki/Wikipedia:Verifiability']verification[/URL][/B]. Please help [URL='https://en.wikipedia.org/wiki/Special:EditPage/Palmitoylethanolamide']improve this article[/URL] by [URL='https://en.wikipedia.org/wiki/Help:Referencing_for_beginners']adding citations to reliable sources[/URL] in this section. Unsourced material may be challenged and removed. [I](February 2020) ([URL='https://en.wikipedia.org/wiki/Help:Maintenance_template_removal']Learn how and when to remove this template message[/URL])[/I][/TD] [/TR] [/TABLE] Palmitoylethanolamide was discovered in 1957.[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Citation_needed']citation needed[/URL][/I]] Indications for its use as an anti-inflammatory and analgesic date from before 1980.[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Citation_needed']citation needed[/URL][/I]] In that year, researchers described what they called "N-(2-hydroxyethyl)-palmitamide" as a natural anti-inflammatory agent, stating, "We have succeeded in isolating a crystalline anti-inflammatory factor from soybean lecithin and identifying it as ([I]S[/I])-(2-hydroxyethyl)-palmitamide. The compound also was isolated from a phospholipid fraction of egg yolk and from hexane-extracted peanut meal."[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Inline_citation#When_you_must_use_inline_citations']This quote needs a citation[/URL][/I]] In 1975, Czech physicians described the results of a clinical trial[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Please_clarify']clarification needed[/URL][/I]] looking at joint pain, where the analgesic action of [URL='https://en.wikipedia.org/wiki/Aspirin']aspirin[/URL] versus PEA were tested; both drugs were reported to enhance joint movements and decrease pain.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Masek1975-14'][14][/URL] In 1970 the drug manufacturer [URL='https://en.wikipedia.org/w/index.php?title=Spofa&action=edit&redlink=1']Spofa[/URL] in Czechoslovakia introduced [URL='https://en.wikipedia.org/w/index.php?title=Impulsin&action=edit&redlink=1']Impulsin[/URL], a tablet dose of PEA, for the treatment and prophylaxis of influenza and other respiratory infections.[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Citation_needed']citation needed[/URL][/I]] In Spain, the company [URL='https://en.wikipedia.org/wiki/Almirall']Almirall[/URL] introduced [URL='https://en.wikipedia.org/wiki/Palmidrol']Palmidrol[/URL] in tablet and suspension forms in 1976, for the same indications.[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Citation_needed']citation needed[/URL][/I]] In the mid-1990s, the relationship between [URL='https://en.wikipedia.org/wiki/Anandamide']anandamide[/URL] and PEA was described;[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Facci1995-15'][15][/URL][[I][URL='https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources']non-primary source needed[/URL][/I]] the expression of [URL='https://en.wikipedia.org/wiki/Mast_cell']mast cell[/URL] receptors sensitive to the two molecules was demonstrated by [URL='https://en.wikipedia.org/wiki/Rita_Levi-Montalcini']Levi-Montalcini[/URL] and coworkers.[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Manual_of_Style/Words_to_watch#Unsupported_attributions']according to whom?[/URL][/I]][[I][URL='https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources']non-primary source needed[/URL][/I]] During this period, more insight into the functions of endogenous fatty acid derivatives emerged, and compounds such as [URL='https://en.wikipedia.org/wiki/Oleamide']oleamide[/URL], palmitoylethanolamide, [URL='https://en.wikipedia.org/w/index.php?title=2-lineoylglycerol&action=edit&redlink=1']2-lineoylglycerol[/URL] and [URL='https://en.wikipedia.org/w/index.php?title=2-palmitoylglycerol&action=edit&redlink=1']2-palmitoylglycerol[/URL] were explored for their capacity to modulate pain sensitivity and inflammation via what at that time was thought to be the endocannabinoid signalling pathway.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Walker2002-16'][16][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Lambert2002-17'][17][/URL] Primary reports also have provided evidence that PEA downregulates hyperactive mast cells in a dose-dependent manner,[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Mazzari1996-18'][18][/URL] and that it alleviates pain elicited in mouse models.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Calignano2001-11'][11][/URL][[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Verifiability']verification needed[/URL][/I]] PEA and related compounds such as anandamide also seem to have synergistic effects in models of pain and analgesia.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Calignano1998-19'][19][/URL] [HEADING=1]Animal models[[URL='https://en.wikipedia.org/w/index.php?title=Palmitoylethanolamide&action=edit§ion=2']edit[/URL]][/HEADING] In a variety of animal models, PEA seems to have some promise;[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:EDITORIALIZING']editorializing[/URL][/I]][[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Citation_needed']citation needed[/URL][/I]] researchers have been able to demonstrate relevant clinical efficacy in a variety of disorders, from multiple sclerosis to neuropathic pain.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Lor%C3%ADa2008-20'][20][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Costa2008-21'][21][/URL] In the mouse [URL='https://en.wikipedia.org/wiki/Behavioural_despair_test']forced swimming test[/URL], palmitoylethanolamide was comparable to [URL='https://en.wikipedia.org/wiki/Fluoxetine']fluoxetine[/URL] for [URL='https://en.wikipedia.org/wiki/Depression_(mood)']depression[/URL].[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Yu2011-22'][22][/URL] An Italian study published in 2011 found that PEA reduced the raised [URL='https://en.wikipedia.org/wiki/Intraocular_pressure']intraocular pressure[/URL] of [URL='https://en.wikipedia.org/wiki/Glaucoma']glaucoma[/URL].[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Gagliano2011-23'][23][/URL] In a spinal trauma model, PEA reduced the resulting neurological deficit via the reduction of mast cell infiltration and activation. PEA in this model also reduced the activation of [URL='https://en.wikipedia.org/wiki/Microglia']microglia[/URL] and [URL='https://en.wikipedia.org/wiki/Astrocytes']astrocytes[/URL].[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Esposito2011-24'][24][/URL] Its activity as an inhibitor of inflammation counteracts reactive [URL='https://en.wikipedia.org/wiki/Astrogliosis']astrogliosis[/URL] induced by [URL='https://en.wikipedia.org/wiki/Beta-amyloid']beta-amyloid[/URL] peptide, in a model relevant for neurodegeneration, probably via the [URL='https://en.wikipedia.org/wiki/Peroxisome_proliferator-activated_receptor_alpha']PPAR-α[/URL] mechanism of action.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Scuderi2011-25'][25][/URL][[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Verifiability']verification needed[/URL][/I]] In models of stroke and other [URL='https://en.wikipedia.org/wiki/Central_nervous_system']CNS[/URL] trauma, PEA exerted neuroprotective properties.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Koch2011-12'][12][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Hansen2010-26'][26][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Garcia-Ovejero2011-27'][27][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Schomacher2008-28'][28][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Skaper1996-29'][29][/URL] [HEADING=1]Animal models of chronic pain and inflammation[[URL='https://en.wikipedia.org/w/index.php?title=Palmitoylethanolamide&action=edit§ion=3']edit[/URL]][/HEADING] Chronic pain and neuropathic pain are indications for which there is high unmet need in the clinic. PEA has been tested in a variety of animal models for chronic and neuropathic pain, because cannabinoids, such as [URL='https://en.wikipedia.org/wiki/THC']THC[/URL], have been proven to be effective in neuropathic pain states.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Ware2010-30'][30][/URL] The analgesic and antihyperalgesic effects of PEA in two models of acute and persistent pain seemed to be explained at least partly via the [I]de novo[/I] neurosteroid synthesis.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Sasso2011-31'][31][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Raso2011-32'][32][/URL] In chronic [URL='https://en.wikipedia.org/wiki/Granulomatous']granulomatous[/URL] pain and inflammation model, PEA could prevent nerve formation and sprouting, mechanical allodynia, and PEA inhibited [URL='https://en.wikipedia.org/wiki/Dorsal_root_ganglia']dorsal root ganglia[/URL] activation, which is a hallmark for winding up in neuropathic pain.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-DeFilippis2011-33'][33][/URL] The mechanism of action of PEA as an analgesic and anti-inflammatory molecule is probably based on different aspects.[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:EDITORIALIZING']editorializing[/URL][/I]][[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Citation_needed']citation needed[/URL][/I]] PEA inhibits the release of both preformed and newly synthesised mast cell mediators, such as [URL='https://en.wikipedia.org/wiki/Histamine']histamine[/URL] and [URL='https://en.wikipedia.org/wiki/TNF-alpha']TNF-alpha[/URL].[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Cerrato2010-34'][34][/URL] PEA, as well as its analogue adelmidrol (di-amide derivative of azelaic acid), can both down-regulate mast cells.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-DeFilippis2009-35'][35][/URL] PEA reduces the expression of [URL='https://en.wikipedia.org/wiki/Cyclooxygenase-2']cyclooxygenase-2[/URL] (COX-2) and [URL='https://en.wikipedia.org/wiki/Inducible_nitric_oxide_synthase']inducible nitric oxide synthase[/URL] (iNOS) and prevents IkB-alpha degradation and p65 [URL='https://en.wikipedia.org/wiki/NF-kappaB']NF-kappaB[/URL] nuclear translocation, the latter related to PEA as an endogenous PPAR-alpha agonist. In 2012 it became clear that PEA can also reduce reperfusion injury and the negative impact of shock on various outcome parameters, such as renal dysfunction, ischemic injury and inflammation, most probably via the PPAR-alpha pathway.[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:EDITORIALIZING']editorializing[/URL][/I]][[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Citation_needed']citation needed[/URL][/I]] Studies have shown that PEA activates activates PPAR-alpha and TRPV1 receptors that control inflammation and the sensation of pain.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-36'][36][/URL] Among the reperfusion and inflammation markers measured PEA could reduce the increase in creatinine, γGT, AST, nuclear translocation of NF-κBp65; kidney MPO activity and MDA levels, nitrotyrosine, PAR and adhesion molecules expression, the infiltration and activation of mast cells and apoptosis.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-DiPaola-37'][37][/URL] The biological responses to PEA dosing in animal models and in humans are being investigated vis-à-vis its involvement in a repair mechanism relevant to patient conditions of chronic inflammation and chronic pain.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Darmani2005-38'][38][/URL][[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Verifiability']verification needed[/URL][/I]] In a model of visceral pain (inflammation of the [URL='https://en.wikipedia.org/wiki/Urinary_bladder']urinary bladder[/URL]) PEA was able to attenuate the viscero-visceral hyper-reflexia induced by inflammation of the urinary bladder, one of the reasons why PEA is currently explored in the painful bladder syndrome.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Jaggar1998-39'][39][/URL] In a different model for bladder pain, the turpentine-induced urinary bladder inflammation in the rat, PEA also attenuated a referred hyperalgesia in a dose-dependent way.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Farquhar-Smith2001-40'][40][/URL] Chronic pelvic pain in patients seem to respond favourably to a treatment with PEA.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Calabr%C3%B2i2010-41'][41][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Indraccoloi2010-42'][42][/URL] [HEADING=1]Activity in non-neuronal cells[[URL='https://en.wikipedia.org/w/index.php?title=Palmitoylethanolamide&action=edit§ion=4']edit[/URL]][/HEADING] [TABLE] [TR] [TD][URL='https://en.wikipedia.org/wiki/File:Question_book-new.svg'][IMG]https://upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png[/IMG][/URL][/TD] [TD]This section [B]needs additional citations for [URL='https://en.wikipedia.org/wiki/Wikipedia:Verifiability']verification[/URL][/B]. Please help [URL='https://en.wikipedia.org/wiki/Special:EditPage/Palmitoylethanolamide']improve this article[/URL] by [URL='https://en.wikipedia.org/wiki/Help:Referencing_for_beginners']adding citations to reliable sources[/URL] in this section. Unsourced material may be challenged and removed. [I](February 2020) ([URL='https://en.wikipedia.org/wiki/Help:Maintenance_template_removal']Learn how and when to remove this template message[/URL])[/I][/TD] [/TR] [/TABLE] PEA, as an [URL='https://en.wikipedia.org/wiki/N-acylethanolamine'][I]N[/I]-acylethanolamine[/URL], has physico-chemical properties comparable to [URL='https://en.wikipedia.org/wiki/Anandamide']anandamide[/URL],[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Please_clarify']clarification needed[/URL][/I]] and, while it is not strictly an endocannabinoid, it is often studied in conjunction with anandamide because of their overlapping synthetic and metabolic pathways.[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources']non-primary source needed[/URL][/I]] [I]N[/I]-acylethanolamines such as PEA often act as signaling molecules, activating receptors and regulating a variety of physiological functions.[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources']non-primary source needed[/URL][/I]] PEA is known to activate intracellular, nuclear and membrane-associated receptors,[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources']non-primary source needed[/URL][/I]] and to regulate many physiological functions related to the inflammatory cascade and chronic pain states.[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources']non-primary source needed[/URL][/I]] Endocannabinoid lipids like PEA are widely distributed in nature, in a variety of plant, invertebrate, and mammalian tissues.[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources']non-primary source needed[/URL][/I]] PEA's mechanism of action sometimes is described as [URL='https://en.wikipedia.org/wiki/Autacoid']Autacoid[/URL] Local Injury Antagonism (acronym ALIA),[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Facci1995-15'][15][/URL] and PEA under this nomenclature is an [URL='https://en.wikipedia.org/w/index.php?title=ALIAmide&action=edit&redlink=1']ALIAmide[/URL]. [URL='https://en.wikipedia.org/wiki/Rita_Levi-Montalcini']Levi-Montalcini[/URL] and coworkers presented evidence in 1993 that lipid amides of the N-acylethanolamine type, such as PEA, are potential prototypes of naturally occurring molecules capable of modulating mast cell activation, and her group used the acronym ALIA in that report.[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources']non-primary source needed[/URL][/I]][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Aloe1993-43'][43][/URL] An [URL='https://en.wikipedia.org/wiki/Autocoid']autocoid[/URL] is a regulating molecule, locally produced. An ALIAmide is an autocoid synthesized on-demand in response to injury, and acts locally to counteract such pathology. Soon after the breakthrough paper of Levi-Montalcini, the mast cell appeared to be an important target for the anti-inflammatory activity of PEA. Since 1993, at least 25 papers have been published on the various effects of PEA on mast cells. These cells are often found in proximity to sensory nerve endings, and their degranulation can enhance the nociceptive signal, the reason why peripheral mast cells are considered to be pro-inflammatory and pro-nociceptive.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Xanthos2011-44'][44][/URL] PEA's activity is currently seen as a new inroad in the treatment of neuropathic pain and related disorders based on overactivation of glia and glia-related cells, such as in diabetes and glaucoma.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Donvito2015-45'][45][/URL] Microglia plays a key role in the [URL='https://en.wikipedia.org/wiki/Pain_wind-up']winding up phenomenon[/URL] and central sensitization.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Nakagawa2010-46'][46][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Guasti2009-47'][47][/URL] [HEADING=1]Clinical relevance[[URL='https://en.wikipedia.org/w/index.php?title=Palmitoylethanolamide&action=edit§ion=5']edit[/URL]][/HEADING] Effects of oral dosing of PEA has been explored in humans, and include clinical trials for a variety of pain states, for inflammatory and pain syndromes.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Indraccoloi2010-42'][42][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-O%27Sullivan2010-48'][48][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Conigliaro2011-49'][49][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Phan2010-50'][50][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Cerrato2011-51'][51][/URL] Daily doses range from 300 to 1200 mg per day.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-52'][52][/URL] In a 2017 systematic meta-analysis involving 10 studies including data from 786 patients receiving PEA for pain-related indications and 512 controls, PEA was found to be associated with pain reduction significantly greater than observed in controls ([I]P[/I] < 0.001).[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-53'][53][/URL] Positive influences have also been observed in dermal applications, specifically atopic eczema, which may be linked to PPAR alpha activation.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-O%27Sullivan2010-48'][48][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Hatano2010-54'][54][/URL][[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Verifiability']verification needed[/URL][/I]] In a 2015 analysis of a double blind placebo controlled study of PEA in sciatic pain, the Numbers Needed to Treat was 1.5. Its positive influence in chronic pain, and inflammatory states such as atopic eczema, seems[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:EDITORIALIZING']editorializing[/URL][/I]] to originate mainly from PPAR alpha activation.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-O%27Sullivan2010-48'][48][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Hatano2010-54'][54][/URL][[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Verifiability']verification needed[/URL][/I]] Since 2012 a number of new trials have been published, among which studies in glaucoma.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Costagliola2014-55'][55][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Pescosolido2014-56'][56][/URL] PEA also seems[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:EDITORIALIZING']editorializing[/URL][/I]] to be one of the factors responsible for the decrease in pain sensitivity during and after sport, comparable to the endogenous opiates (endorphines).[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Koltyn2014-57'][57][/URL][[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Verifiability']verification needed[/URL][/I]] From a clinical perspective the most important and promising indications for PEA are linked to neuropathic and chronic pain states, such as diabetic neuropathic pain, sciatic pain, CRPS, pelvic pain and entrapment neuropathic pain states.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Darmani2005-38'][38][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Indraccoloi2010-42'][42][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Conigliaro2011-49'][49][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Phan2010-50'][50][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Petrosino2010-58'][58][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-pmid23658493-59'][59][/URL] In a blind trial reported in a conference proceeding, patients affected by pain from [URL='https://en.wikipedia.org/wiki/Synovitis']synovitis[/URL] or [URL='https://en.wikipedia.org/wiki/Temporomandibular_joint']TMJ[/URL] osteoarthritis (N=25, in total[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Please_clarify']clarification needed[/URL][/I]]) were randomly assigned to PEA or ibuprofen groups for two weeks; the decrease in pain reported after two weeks was significantly higher for the PEA-treated group, likewise for improved masticatory function.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-60'][60][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-61'][61][/URL][[I][URL='https://en.wikipedia.org/wiki/Wikipedia:NOTRS']better source needed[/URL][/I]] In 2012, 20 patients with thalidomide and bortezomib induced neuropathy were reported to have improved nerve functions and less pain after a two-month treatment with PEA.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Truini2012-62'][62][/URL] The authors pointed out that although a placebo effect might play a role in the reported pain relief, the changes in neurophysiological measures clearly indicated that PEA exerted a positive action on the myelinated fibre groups. Sixteen men and fourteen women with two major types of neuropathic pain refractory to analgesic treatment—peripheral diabetic neuropathy (4 men, 7 women) or post-herpetic neuralgia (12 men, 7 women)[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-63'][63][/URL]—whose symptoms spanned eight pain categories ("burning", "osteoarticular", "piercing", etc.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-64'][64][/URL]) who were under prior treatment with pregabalin were transferred to PEA, after which pregabalin treatment was gradually reintroduced; all were responding well after 45 days, and presented significant decreases in pain scores (without drug-drug interactions).[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Verifiability']verification needed[/URL][/I]][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-65'][65][/URL] In 2013, a metareview was published on the clinical efficacy and safety of PEA in the treatment of the [URL='https://en.wikipedia.org/wiki/Common_cold']common cold[/URL] and [URL='https://en.wikipedia.org/wiki/Influenza']influenza[/URL], based on reports from six double-blind, placebo, [URL='https://en.wikipedia.org/wiki/Randomized_controlled_trial']randomized controlled trials[/URL],[[I][URL='https://en.wikipedia.org/wiki/Wikipedia:Verifiability']verification needed[/URL][/I]] addressing PEA's proposed anti-inflammatory and retinoprotectant effects.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-pmid24066256-66'][66][/URL] In 2019, significant increases in [URL='https://en.wikipedia.org/wiki/Fatty_acid_amides']fatty acid amides[/URL] including PEA, [URL='https://en.wikipedia.org/wiki/Arachidonoylethanolamide']arachidonoylethanolamide[/URL], and [URL='https://en.wikipedia.org/wiki/Oleoylethanolamide']oleoylethanolamide[/URL] were noted in a Scottish woman with a previously undocumented variant of [URL='https://en.wikipedia.org/wiki/Congenital_insensitivity_to_pain']congenital insensitivity to pain[/URL]. This was found to be a result of a combination of a hypomorphic [URL='https://en.wikipedia.org/wiki/Single_nucleotide_polymorphism']single nucleotide polymorphism[/URL] of [URL='https://en.wikipedia.org/wiki/Fatty_acid_amide_hydrolase']fatty acid amide hydrolase[/URL] (FAAH), alongside a mutation of the [URL='https://en.wikipedia.org/wiki/Pseudogene']pseudogene[/URL], [URL='https://en.wikipedia.org/wiki/FAAH-OUT']FAAH-OUT[/URL]. The pseudogene was previously considered to be [URL='https://en.wikipedia.org/wiki/Non-coding_DNA']non-coding DNA[/URL], FAAH-OUT was found to be capable of modulating the expression of FAAH, making it a possible future target for novel analgesia/anxiolytic drug development.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-67'][67][/URL][URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-68'][68][/URL] In 2020, PEA has been suggested as a drug that may prove beneficial for the treatment of lung inflammation caused by SARS-CoV-2 infection.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-69'][69][/URL] A pharmaceutical company called FSD Pharma have entered PEA into a Phase 1 clinical trial under the name FSD-201, and has approval from the FDA for progressing to Phase 2a for this indication.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-70'][70][/URL] [HEADING=1]Metabolism[[URL='https://en.wikipedia.org/w/index.php?title=Palmitoylethanolamide&action=edit§ion=6']edit[/URL]][/HEADING] PEA is metabolized by the cellular enzymes [URL='https://en.wikipedia.org/wiki/Fatty_acid_amide_hydrolase']fatty acid amide hydrolase[/URL] (FAAH) and [URL='https://en.wikipedia.org/wiki/N-acylethanolamine_acid_amide_hydrolase']N-acylethanolamine acid amide hydrolase[/URL] (NAAA), the latter of which has more specificity toward PEA over other fatty acid amides.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-Tsuboi2007-71'][71][/URL] [HEADING=1]Safety[[URL='https://en.wikipedia.org/w/index.php?title=Palmitoylethanolamide&action=edit§ion=7']edit[/URL]][/HEADING] PEA is generally considered safe, and without adverse drug reactions (ADRs) or drug interactions. A 2016 study assessing safety claims in sixteen clinical trials, six case reports/pilot studies and a meta‐analysis of PEA as an analgesic, concluded that for treatment periods up to 49 days, clinical data argued against serious ADRs at an incidence of 1/200 or greater.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-72'][72][/URL] A 2016 pooled meta-analysis involving twelve studies found that no serious ADRs were registered and/or reported.[URL='https://en.wikipedia.org/wiki/Palmitoylethanolamide#cite_note-73'][73][/URL] No data on interactions with PEA have been reported. Based on its mechanism, PEA may be considered likely to interact with other PPAR-α agonists used to treat high triglycerides; this remains unconfirmed. [/QUOTE]
Insert quotes…
Verification
Post reply
Forums
Paranormal Forum
Health, Well-Being & Alternative Medicine
Need health? Go take a PEA
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top